Tasly Pharmaceutical Group Co., Ltd (SHA:600535)

China flag China · Delayed Price · Currency is CNY
15.44
-0.06 (-0.39%)
Apr 2, 2025, 2:45 PM CST
-4.16%
Market Cap 23.16B
Revenue (ttm) 8.50B
Net Income (ttm) 955.59M
Shares Out 1.49B
EPS (ttm) 0.64
PE Ratio 24.23
Forward PE 20.26
Dividend 0.53 (3.51%)
Ex-Dividend Date Mar 26, 2025
Volume 11,601,200
Average Volume 11,982,768
Open 15.45
Previous Close 15.50
Day's Range 15.38 - 15.61
52-Week Range 12.24 - 17.77
Beta 0.44
RSI 62.86
Earnings Date Mar 4, 2025

About SHA:600535

Tasly Pharmaceutical Group Co., Ltd engages in the pharmaceutical business in China and internationally. The company provides prescription drugs covering various therapeutic areas, including cardiovascular and cerebrovascular, hepato-biliary-pancreatic, respiratory system, diabetes, tumor immunity, gastrointestinal disease, gynecological, rheumatism, soothe the nerves, pruritus, and andrological areas, as well as over-the-counter drugs. Tasly Pharmaceutical Group Co., Ltd was founded in 1994 and is headquartered in Tianjin, China. [Read more]

Sector Healthcare
Founded 1994
Employees 10,958
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 600535
Full Company Profile

Financial Performance

In 2024, SHA:600535's revenue was 8.50 billion, a decrease of -2.03% compared to the previous year's 8.67 billion. Earnings were 955.59 million, a decrease of -10.78%.

Financial Statements

News

There is no news available yet.